Cancer is a leading cause of death worldwide. Cervical cancer caused by human papillomavirus (HPV) is a major health problem in women. DNA vaccines are a perfect approach to immunization, but their potency in clinical trials has been insufficient for generating effective immunity, which may be related to the degradation of the DNA via nucleases, poor delivery to antigen-presenting cells (APCs), and insufficient uptake of DNA plasmids by cells upon injection. Archaeosome is a nano-delivery systems based on liposomes with their immunological role have been developed for gene delivery. In this study, human papillomavirus type 16 genes, containing truncated L1, E6, and E7, were simultaneously used in combination therapy with archaeosome and assessed in vivo. Findings supported that archaeosomes promotes immune responses to DNA vaccines and a long-term CTL response was generated with a low antigen dose. Combination therapy with archaeosome/L1/E6/E7 vaccines exhibited a strong cytolytic activity against tumor cells and induced prophylactic and therapeutic effect against the development of tumor in the animal model.

癌症是全球主要的死亡原因。由人类乳头瘤病毒（HPV）引起的宫颈癌是女性的主要健康问题。DNA疫苗是一种理想的免疫方法，但是在临床试验中其效力不足以产生有效的免疫力，这可能与DNA通过核酸酶的降解，向抗原呈递细胞（APC）的递送不良以及摄取不足有关。注射细胞后DNA质粒的分离。考古小体是基于脂质体的纳米传递系统，其具有免疫学作用，已经开发用于基因传递。在这项研究中，包含截短的L1，E6和E7的人类乳头瘤病毒16型基因被同时用于古细菌的联合治疗，并在体内进行了评估。研究结果支持古细菌促进对DNA疫苗的免疫反应，并以低抗原剂量产生了长期CTL反应。在动物模型中，古细菌/ L1 / E6 / E7疫苗的联合治疗对肿瘤细胞表现出很强的溶细胞活性，并诱导了对肿瘤发展的预防和治疗作用。